Business
Oncopeptides publishes Q1 report 2026
Oncopeptides publishes Q1 report
About this update from Oncopeptides Ab
Stockholm – May 13, 2026 – Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on difficult-to-treat cancers, today publishes the report for the first quarter 2026.“Oncopeptides delivered a strong start to 2026, with first-quarter net sales reaching SEK 25.4 million, representing a 91 percent increase compared to the same period in 2025”, says Sofia Heigis, CEO of Oncopeptides. “This performance reflects continued strong demand for Pepaxti in Italy where the commercial launch has continued to exceed our initial expectations combined with a return to solid growth numbers in Germany. While we navigate a rapidly evolving therapeutic landscape, this quarter marks an important step in both our commercial execution and our strategic evolution as a company.”Financial overview January-MarchNet sales amounted to SEK 25.4 (13.3) millionOperating profit amounted to SEK -37.5 (-59.8) millionProfit after tax amounted to SEK -32.2 (-60.7) millionEarnings per share, before and after dilution -0.12 (-0.29) SEKCash and cash equivalents at the end of the period amounted to SEK 205.2 (107.2) millionSignificant events January-MarchOncopeptides announces rights issue of approx. SEK 200 millionOncopeptides secures fast-track designation for Window-of-Opportunity study in glioblastomaEuropean Journal of Haematology: Real-World Data reinforces Pepaxti’s role in treatment sequencing for multiple myelomaOncopeptides initiates MARINA study to strengthen real-world evidence for Pepaxti in GermanyEvents after the periodPreclinical data on novel NK-Cell engager was presented at the AACR Annual Meeting 2026Oncopeptides intends to submit a type II variation to expand Pepaxti label to include third line treatment Financial overview of the group(SEK thousand)2026Jan-Mar2025Jan-Mar2025Jan-Dec2024Jan-DecNet sales25,38413,26771,11831,648Operating profit-37,531-59,835-224,651-283,498Profit after tax-32,185-60,669-249,585-284,607Earnings per share, before and after dilution (SEK)-0.12-0.29-1.10-1.71Cash flow from operating activities-45,592-68,317-216,493-260,570Cash at the end of the period205,154107,22582,255178,536Conference call for investors, analysts and the media Investors, financial analysts, and media are invited to participate in a webcast and a subsequent Q&A session at 09:00 CET today. The presentation will be hosted by Sofia Heigis, CEO, t...